Aliases & Classifications for Adenocarcinoma

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 12 29 55 6 44 15 73
Adenocarcinomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:299
MeSH 44 D000230
NCIt 50 C2852
UMLS 73 C0001418

Summaries for Adenocarcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinomas, is related to aggressive digital papillary adenocarcinoma and mucinous adenocarcinoma. An important gene associated with Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Apoptotic Pathways in Synovial Fibroblasts. The drugs Abraxane and Cervarix have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1184)
# Related Disease Score Top Affiliating Genes
1 aggressive digital papillary adenocarcinoma 34.9 HRAS KRAS PIK3CA
2 mucinous adenocarcinoma 34.9 CDKN2A EGFR KRAS MLH1
3 small intestinal adenocarcinoma 34.8 BRAF CTNNB1 EGFR ERBB2 KRAS
4 cervical adenocarcinoma 34.6 CDKN2A EGFR ERBB2 TP53
5 ovary adenocarcinoma 34.6 ERBB2 HRAS KRAS TP53
6 ethmoid sinus adenocarcinoma 34.6 EGFR HRAS PIK3CA
7 barrett's adenocarcinoma 34.5 CDKN2A ERBB2 KRAS TP53
8 vulvar adenocarcinoma 34.5 RB1 TP53
9 nasal cavity adenocarcinoma 34.4 CDKN2A HRAS KRAS TP53
10 cecum adenocarcinoma 34.4 HRAS KRAS MLH1
11 gastric papillary adenocarcinoma 34.4 ERBB2 TP53
12 endometrial adenocarcinoma 34.2 AKT1 CDKN2A EGFR ERBB2 KRAS MLH1
13 rare adenocarcinoma of the breast 34.1 AKT1 KRAS PIK3CA TP53
14 pancreas adenocarcinoma 34.1 AKT1 CDKN2A CTNNB1 EGFR ERBB2 HRAS
15 colorectal adenocarcinoma 34.1 BRAF CTNNB1 EGFR HRAS KRAS MLH1
16 fallopian tube endometrioid adenocarcinoma 34.0 CDKN2A ERBB2
17 bile duct adenocarcinoma 34.0 EPCAM HRAS KRAS TP53
18 adenosquamous carcinoma 34.0 EGFR KRAS TP53
19 barrett esophagus 33.9 ASCC1 CDKN2A CTHRC1 ERBB2 TP53
20 esophagus adenocarcinoma 33.6 ERBB2 HNF1A-AS1 PIK3CA SMAD4 TP53
21 uterine corpus serous adenocarcinoma 33.6 ERBB2 TP53
22 suppression of tumorigenicity 12 33.5 AKT1 BRAF CTNNB1 HRAS PIK3CA SMAD4
23 renal cell carcinoma, papillary, 1 33.3 BRAF ERBB2 HRAS PIK3CA TP53
24 adenoid cystic carcinoma 33.2 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
25 bile duct carcinoma 33.2 EGFR PIK3CA TP53
26 primary peritoneal carcinoma 33.2 EGFR ERBB2 TP53
27 colorectal adenoma 33.1 CTNNB1 HRAS KRAS MLH1 TP53
28 cystadenocarcinoma 33.1 AKT1 ERBB2 HRAS PIK3CA TP53
29 adenoma 33.0 BRAF CTNNB1 KRAS MLH1 SMAD4 TGFBR2
30 breast adenocarcinoma 32.9 AKT1 EGFR ERBB2 H19 KRAS PIK3CA
31 hidradenocarcinoma 32.7 EGFR ERBB2 TP53
32 ovarian serous cystadenocarcinoma 32.6 BRAF ERBB2 HRAS PIK3CA TP53
33 rectal neoplasm 32.5 HRAS KRAS MLH1 TP53
34 serous cystadenocarcinoma 32.4 AKT1 ERBB2 HRAS PIK3CA TP53
35 gastric adenocarcinoma 31.9 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
36 peutz-jeghers syndrome 31.7 CTNNB1 SMAD4 TP53
37 familial adenomatous polyposis 31.5 CTNNB1 KRAS MLH1 TP53
38 mature teratoma 31.5 BRAF KRAS TP53
39 gastrointestinal stromal tumor 31.4 AKT1 BRAF CDKN2A EGFR KRAS TP53
40 transitional cell carcinoma 31.4 CDKN2A EGFR ERBB2 HRAS TP53
41 small cell cancer of the lung 31.3 AKT1 CDKN2A EGFR PIK3CA RB1 TP53
42 colitis 31.3 AKT1 CTNNB1 MLH1 SMAD4
43 acinar cell carcinoma 31.3 CTNNB1 SMAD4 TP53
44 sarcoma 31.3 BRAF HRAS KRAS PIK3CA RB1 TP53
45 lung cancer susceptibility 3 31.2 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
46 cervical squamous cell carcinoma 31.2 CDKN2A CTNNB1 TP53
47 esophageal cancer 31.2 AKT1 CDKN2A CTNNB1 EGFR ERBB2 H19
48 lung squamous cell carcinoma 31.1 AKT1 BRAF CDKN2A EGFR HRAS KRAS
49 li-fraumeni syndrome 31.1 CDKN2A EGFR MLH1 TP53
50 ovarian cancer 1 31.1 AKT1 ERBB2 HRAS KRAS PIK3CA TP53

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 55)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.16 HRAS BRAF EGFR PIK3CA KRAS
2 Decreased viability GR00106-A-0 11.16 KRAS
3 Decreased viability GR00107-A-1 11.16 TGFBR2
4 Decreased viability GR00221-A-1 11.16 HRAS TGFBR2 AKT1 CDKN2A EGFR PIK3CA
5 Decreased viability GR00221-A-2 11.16 HRAS AKT1 PIK3CA KRAS
6 Decreased viability GR00221-A-3 11.16 ERBB2 HRAS TGFBR2 AKT1 CDKN2A
7 Decreased viability GR00221-A-4 11.16 ERBB2 TGFBR2 AKT1 CDKN2A BRAF EGFR
8 Decreased viability GR00301-A 11.16 BRAF KRAS
9 Decreased viability GR00381-A-1 11.16 BRAF KRAS
10 Decreased viability GR00402-S-2 11.16 ERBB2 HRAS TGFBR2 AKT1 CDKN2A BRAF
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.38 RB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.38 CTNNB1 KRAS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.38 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.38 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.38 PIK3CA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.38 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.38 RB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.38 RB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.38 BRAF
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.38 PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.38 PIK3CA AKT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.38 BRAF PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.38 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.38 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.38 PIK3CA RB1 KRAS BRAF CTNNB1 AKT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.38 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.38 BRAF
28 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.38 KRAS
29 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.38 CTNNB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.38 RB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.38 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.38 BRAF
33 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.38 BRAF
34 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.38 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.38 PIK3CA AKT1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.38 RB1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.38 BRAF CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.38 PIK3CA KRAS CTNNB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.38 RB1 KRAS AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.38 RB1 KRAS
41 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.38 CTNNB1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.38 AKT1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.38 CTNNB1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.38 CTNNB1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.38 AKT1 CTNNB1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.38 AKT1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.38 KRAS
48 Decreased viability in esophageal squamous lineage GR00235-A 10.15 BRAF CDKN2A CTNNB1 ERBB2 HRAS KRAS
49 Decreased cell migration GR00055-A-1 10.06 AKT1 BRAF CTNNB1 EGFR ERBB4 HRAS
50 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.91 CTNNB1 EGFR EPCAM ERBB2 ERBB4 HRAS

MGI Mouse Phenotypes related to Adenocarcinoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.53 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
2 cardiovascular system MP:0005385 10.5 HRAS KRAS PIK3CA RB1 SMAD4 AKT1
3 endocrine/exocrine gland MP:0005379 10.5 ERBB2 ERBB4 HRAS KRAS MLH1 PIK3CA
4 behavior/neurological MP:0005386 10.48 KRAS PIK3CA RB1 SMAD4 TGFBR2 TP53
5 embryo MP:0005380 10.48 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
6 homeostasis/metabolism MP:0005376 10.47 RB1 SMAD4 TGFBR2 TP53 AKT1 BRAF
7 growth/size/body region MP:0005378 10.44 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
8 digestive/alimentary MP:0005381 10.42 KRAS MLH1 RB1 SMAD4 TGFBR2 TP53
9 mortality/aging MP:0010768 10.41 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
10 integument MP:0010771 10.39 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
11 immune system MP:0005387 10.37 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
12 craniofacial MP:0005382 10.36 BRAF CTNNB1 EGFR ERBB2 ERBB4 HRAS
13 nervous system MP:0003631 10.36 ERBB4 HRAS KRAS PIK3CA RB1 SMAD4
14 hematopoietic system MP:0005397 10.35 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
15 muscle MP:0005369 10.34 CTHRC1 CTNNB1 EGFR ERBB2 ERBB4 KRAS
16 neoplasm MP:0002006 10.32 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
17 liver/biliary system MP:0005370 10.26 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
18 normal MP:0002873 10.22 KRAS RB1 SMAD4 TGFBR2 TP53 EGFR
19 adipose tissue MP:0005375 10.18 AKT1 BRAF EGFR PIK3CA RB1 TGFBR2
20 hearing/vestibular/ear MP:0005377 10.13 BRAF CTHRC1 CTNNB1 EGFR KRAS RB1
21 no phenotypic analysis MP:0003012 10.09 RB1 TP53 CDKN2A CTNNB1 EGFR EPCAM
22 limbs/digits/tail MP:0005371 10.08 CTNNB1 EGFR ERBB2 KRAS RB1 SMAD4
23 reproductive system MP:0005389 10.07 MLH1 PIK3CA RB1 SMAD4 TP53 AKT1
24 respiratory system MP:0005388 9.97 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
25 renal/urinary system MP:0005367 9.92 TP53 BRAF CTNNB1 EGFR HRAS KRAS
26 pigmentation MP:0001186 9.91 BRAF CDKN2A CTNNB1 EGFR KRAS RB1
27 skeleton MP:0005390 9.8 AKT1 BRAF CDKN2A CTHRC1 CTNNB1 EGFR
28 vision/eye MP:0005391 9.32 CTNNB1 EGFR KRAS BRAF CDKN2A MLH1

Drugs & Therapeutics for Adenocarcinoma

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
3
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
4
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
5
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
6
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
7
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
8
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
9
Iressa 18 49 GEFITINIB AstraZeneca May 2003
10
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
11
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1037)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 84093 441203 2767
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 446556 60843
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
4
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
5
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Clarithromycin Approved Phase 4 81103-11-9 84029
8
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 443-48-1 4173
9
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
10
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
11
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
12
Desflurane Approved Phase 4 57041-67-5 42113
13
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
14
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
15
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
16
Cefazolin Approved Phase 4 25953-19-9 656510 33255
17
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
18
Propranolol Approved, Investigational Phase 4,Phase 2,Not Applicable 525-66-6 4946
19
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
20
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
21
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
22
Ethiodized oil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 8008-53-5
23
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
24
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
25
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 198153-51-4 5360545
26
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
27
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
28
Iron Approved Phase 4,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
29
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
30
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 97682-44-5, 100286-90-6 60838
31
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
32
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
33
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
34
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
35
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 5284616 6436030 46835353
37
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
38
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 51-43-4 5816
39
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 329-65-7 838
40
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 56420-45-2 41867
41
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 2 142340-99-6 60871
42
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
43
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
44
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
45
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68538-85-2
46
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
47
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
48
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
49
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
50
Zinc Approved, Investigational Phase 4,Phase 1,Not Applicable 7440-66-6 23994

Interventional clinical trials:

(show top 50) (show all 7171)
# Name Status NCT ID Phase Drugs
1 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
2 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
3 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
4 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
5 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
6 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
7 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
8 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
9 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
10 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
11 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
12 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
13 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
14 RFA for Small HCC With No-touch Technique Using Octopus Electrode Unknown status NCT02832882 Phase 4
15 RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode Unknown status NCT02806076 Phase 4
16 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
17 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
18 Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma Unknown status NCT02504983 Phase 4 sorafenib
19 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
20 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
21 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
22 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
23 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
24 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
25 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
26 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
27 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
28 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
29 Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) Unknown status NCT01409499 Phase 4 sorafenib
30 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
31 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
32 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
33 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
34 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
35 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
36 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
37 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
38 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
39 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
40 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
41 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
42 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
43 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4
44 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
45 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
46 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
47 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
48 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
49 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4 rabeprazole;placebo
50 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: adenocarcinoma

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

# Genetic test Affiliating Genes
1 Adenocarcinoma 29

Anatomical Context for Adenocarcinoma

MalaCards organs/tissues related to Adenocarcinoma:

41
Lung, Prostate, Liver, Kidney, Breast, Colon, Pancreas

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 16013)
# Title Authors Year
1
Histology of colorectal adenocarcinoma with double somatic mismatch repair mutations is indistinguishable from those caused by lynch syndrome. ( 29723603 )
2018
2
SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )
2018
3
Large Cell Carcinoma with Adenocarcinoma in Lung. ( 29544586 )
2018
4
Cytological features of hepatoid adenocarcinoma of the gallbladder: A case report with immunocytochemical analyzes. ( 29637715 )
2018
5
Lycopene-rich extract from red guava (Psidium guajava L.) displays cytotoxic effect against human breast adenocarcinoma cell line MCF-7 via an apoptotic-like pathway. ( 29433206 )
2018
6
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )
2018
7
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
8
Gastric-type Endocervical Adenocarcinoma Involving the Endometrium and Clinically Mimicking Endometrial Neoplasia: A Diagnostic Challenge. ( 29683820 )
2018
9
Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution. ( 29683879 )
2018
10
Histopathologic Features of Colorectal Adenoma and Adenocarcinoma Developing Within Inflammatory Polyps in Miniature Dachshunds. ( 29852840 )
2018
11
MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1. ( 29765447 )
2018
12
Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp. ( 29417386 )
2018
13
Effects of long noncoding RNA SPRY4-IT1-mediated EZH2 on the invasion and migration of lung adenocarcinoma. ( 28796375 )
2018
14
<i>Helicobacter pylori</i> eradication treatment and the risk of gastric adenocarcinoma in a Western population. ( 29382776 )
2018
15
A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. ( 29700411 )
2018
16
Combination of arginine, glutamine, and omega-3 fatty acid supplements for perioperative enteral nutrition in surgical patients with gastric adenocarcinoma or gastrointestinal stromal tumor (GIST): A prospective, randomized, double-blind study. ( 29848836 )
2018
17
Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )
2018
18
Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study. ( 29972732 )
2018
19
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
20
Frequency of Mismatch Repair Protein Deficiency in a Puerto Rican Population with Colonic Adenoma and Adenocarcinoma. ( 29976631 )
2018
21
Adenocarcinoma of Pigmented Ciliary Epithelium in a Child With Aicardi Syndrome and Congenital Microphthalmia With Cyst. ( 29342031 )
2018
22
Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. ( 29551085 )
2018
23
Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. ( 29608452 )
2018
24
Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. ( 29973215 )
2018
25
In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )
2018
26
Metastatic mediastinal mature teratoma with malignant transformation in a young man with an adenocarcinoma in a Klinefelter's syndrome: Case report and review of the literature. ( 29673950 )
2018
27
Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube. ( 29670794 )
2018
28
A Six-Gene Signature Predicts Clinical Outcome of Gastric Adenocarcinoma. ( 29848271 )
2018
29
Cellular mechanism of resistance of human colorectal adenocarcinoma cells against apoptosis-induction by Russell's Viper venom l-amino acid oxidase (Rusvinoxidase). ( 29702182 )
2018
30
PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. ( 28924059 )
2018
31
Hepatobiliary and Pancreatic: Hepatic nodules in a patient with familial adenomatous polyposis and colorectal adenocarcinoma. ( 29284077 )
2018
32
Pulmonary Adenocarcinoma Mimicking Desquamative Interstitial Pneumonia: Report of 2 Cases With Genetic Analysis. ( 29720004 )
2018
33
Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population. ( 29806596 )
2018
34
Effects of carvacrol on human fibroblast (WS-1) and gastric adenocarcinoma (AGS) cells in vitro and on Wistar rats in vivo. ( 29442269 )
2018
35
Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. ( 29540182 )
2018
36
Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. ( 29474242 )
2018
37
Subhyaloid hemorrhage as the first presenting sign of gastric adenocarcinoma. ( 29310953 )
2018
38
Reduced Expression of Deubiquitinase USP33 Is Associated with Tumor Progression and Poor Prognosis of Gastric Adenocarcinoma. ( 29802710 )
2018
39
Targeting dendritic cells in pancreatic ductal adenocarcinoma. ( 29946224 )
2018
40
miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. ( 28870889 )
2018
41
Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. ( 29452076 )
2018
42
Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )
2018
43
Tumor of the Turkish saddle with endocrine disorders as the first manifestation of gastric adenocarcinoma. ( 29385110 )
2018
44
Geographic variation in molecular subtype for gastric adenocarcinoma. ( 29960981 )
2018
45
Mucinous Adenocarcinoma of the Scalp: Primary Cutaneous Neoplasm Versus Underlying Metastatic Disease. ( 29876191 )
2018
46
Localized lymphoid hyperplasia of the spleen mimicking metastatic colorectal adenocarcinoma. ( 29952067 )
2018
47
Ro60/SSA levels are increased and promote the progression of pancreatic ductal adenocarcinoma. ( 29274781 )
2018
48
Are exon 19 deletions and L858R different in early stage lung adenocarcinoma? ( 29026990 )
2018
49
International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. ( 29135516 )
2018
50
Contrast-enhanced ultrasound findings of gallbladder adenocarcinoma with sarcomatoid carcinoma accompanied by intrahepatic metastasis: A case report and literature review. ( 29794755 )
2018